Review of 2022 WHO guidelines on the control and elimination of schistosomiasis
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(22)00221-3
- PMID
- 35594896
- PMCID
- —
- OpenAlex
- W4280592334
- Study type
- Guideline
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The review is relevant to policy and program implementation because it describes guidance intended to improve control and support elimination efforts. It also frames the implications of expanded treatment coverage for public health practice.
Structured evidence summary
Research question
The article reviews the 2022 WHO guidance for controlling and eliminating schistosomiasis and summarizes the rationale for updating earlier preventive chemotherapy policy.
Study design
A peer-reviewed review article summarizing WHO guideline recommendations and their historical context. The abstract identifies it as a Review written by the Schistosomiasis Guidelines Development Group and international partners.
Population and setting
The discussion is global in scope and centered on schistosomiasis in endemic settings. The abstract highlights school-aged children and expands preventive chemotherapy eligibility to people aged 2 years and older.
Main findings
The abstract says WHO published six recommendations in 2022 to update schistosomiasis control strategy. Reported changes include broader preventive chemotherapy eligibility, a lower prevalence threshold for annual treatment, and more frequent treatment.
Public-health relevance
The review is relevant to policy and program implementation because it describes guidance intended to improve control and support elimination efforts. It also frames the implications of expanded treatment coverage for public health practice.
Important limitations
No study limitations are stated in the supplied abstract. This summary is limited to the single provided abstract and metadata, so original-paper review is needed for decision-grade interpretation.
GIDS interpretation
This item is easy to interpret as guideline-related literature because it directly discusses WHO recommendations and their implementation context. It provides contextual evidence on policy updates, not a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.